A Phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma
Refereed conference paper presented and published in conference proceedings

香港中文大學研究人員

全文

其它資訊
著者LIM H Y, YEN C J, TAK W Y, HEO J, CHOI H J, LIN C Y, YOON J H, HSU C, RAU K M, POON R, YEO Winnie, PARK J W, TAY M H, HSIEH W S, KAPPELER C, RAJAGOPALAN P, KRISSEL H
會議名稱Annual Meeting of the American Society of Clinical Oncology
會議開始日01.06.2012
會議國家/地區美國
會議論文集題名Annual Meeting of the American Society of Clinical Oncology
出版年份2012
月份6
出版地United States of America
頁次1
語言英式英語
關鍵詞Hepaatocellular Carcinoma

上次更新時間 2018-19-01 於 18:21